Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Shanghai Pharmaceuticals Holding Co ( (HK:2607) ) is now available.
Shanghai Pharmaceuticals Holding Co., Ltd. has announced its Annual General Meeting scheduled for June 26, 2025, where several key proposals will be considered. These include the approval of the 2024 Annual Report, financial plans for 2025, profit distribution, re-appointment of the accounting firm, and issuance of corporate bonds, which could significantly impact the company’s financial strategy and stakeholder interests.
The most recent analyst rating on (HK:2607) stock is a Buy with a HK$15.70 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
More about Shanghai Pharmaceuticals Holding Co
Shanghai Pharmaceuticals Holding Co., Ltd. is a joint stock company based in the People’s Republic of China, primarily engaged in the pharmaceutical industry. The company focuses on the production and distribution of pharmaceutical products and services, catering to a wide market within the healthcare sector.
Average Trading Volume: 5,337,783
Technical Sentiment Signal: Sell
Current Market Cap: HK$65.5B
Learn more about 2607 stock on TipRanks’ Stock Analysis page.